#Pharmaceutical Analytical Testing Outsourcing Market

[industrynewsupdates]

Pharmaceutical Analytical Testing Outsourcing Market 2024-2030: Trends and Opportunities

The global pharmaceutical analytical testing outsourcing market size was valued at USD 8.3 billion in 2023 and is projected to grow at a CAGR of 8.4% from 2024 to 2030.

Growth in the market can be attributed due to increasing focus toward safety, & quality; regulation, pricing benefits of outsourcing, and rising number of end use. Besides, increasing R&D investment is one of the critical sustainability strategies adopted by market players. As, not all companies have an infrastructure for analytical testing. Therefore, outsourcing these operations is a suitable option, which helps to save time and cost.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Analytical Testing Outsourcing Market 

Other factors, such as the changing regulations for in vivo and in vitro tests, are also expected to propel the growth of the market for pharmaceutical analytical testing outsourcing. Besides, high demand for quality generic drugs, analytical testing methods, improved the quality and transparency of the review & approval process, and encourage new drug R&D in line with global development is anticipated to fuel the market growth.

In addition, innovation or new product development is directly proportional to the demand for testing services due to pricing concerns, competitive pressures, and lead-time to market, companies are opting for outsourcing of testing services. Moreover, focus on customized care and technological advancements, which has resulted in rapid development of new products. Likewise, development of biosimilar, combination products, and other innovative medicines has fueled the demand for pharmaceutical analytical testing services.  

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global pharmaceutical regulatory affairs market size was estimated at USD 8.84 billion in 2023 and is projected to grow at a CAGR of 7.16% from 2024 to 2030. 

• The global pharmaceutical packaging market size was valued at USD 139.37 billion in 2023 and is expected to grow a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030.

Pharmaceutical Analytical Testing Outsourcing Market Segmentation

Grand View Research has segmented the prebiotic ingredient market based on type, application, and region:

Type Outlook (Revenue, USD Million, 2017 - 2028)

• Inulin

• Oligosaccharide (MOS/GOS/FOS)

• Others

Applications Outlook (Revenue, USD Million, 2017 - 2028)

• Food & Beverage

• Dietary Supplements

• Others

Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America

• Europe

• Asia Pacific

• Central & South America

• Middle East & Africa

Key Companies & Market Share Insights

Companies' are focusing on innovating new types of prebiotic ingredients to meet the increasing demand. New players are entering the market owing to low market entry barriers and higher market potential. The increasing demand for prebiotic ingredients offers an opportunity for product development in the regions of high demand. Some of the prominent players in the global prebiotic ingredient market include:

• Beneo-Orafti SA

• Tereos Group

• Ingredion Inc.

• Cargill Inc.

• DowDuPont Inc

• Royal FrieslandCampina N.V.

• Kerry Group

• Cosucra-groupe Warcoing SA

• Sensus BV

Recent Developments

• In December 2023, Agno Pharma acquired Lubrizol Particle Sciences Inc. The acquisition encompasses the drug product formulation technology integral to Particle Sciences Inc. including the PA, Bethlehem development & manufacturing site.

• In November 2023, Eurofins acquired Quasfar supporting the pharmaceutical industry in Latin America, enhancing its capabilities in R&D, providing support in the early stages of pharmaceutical product development.

Order a free sample PDF of the Pharmaceutical Analytical Testing Outsourcing Market Intelligence Study, published by Grand View Research. 

[blog-site-for-market-research]

Market Report: Delving into the Pharmaceutical Analytical Testing Outsourcing Market Size and Share

Market Overview –

The Pharmaceutical Analytical Testing Outsourcing Market refers to the sector within the pharmaceutical industry where companies outsource their analytical testing needs to specialized service providers. This market has witnessed significant growth in recent years due to the increasing complexity of drug formulations and the stringent regulatory requirements imposed by health authorities worldwide.

Outsourcing Analytical Testing in the pharmaceutical industry is witnessing significant traction as companies seek cost-effective and specialized solutions. Outsourcing firms offer expertise in analytical testing, ensuring regulatory compliance and quality assurance. This trend is driven by the complexity of testing requirements and the need for efficient resource allocation. The market for outsourcing analytical testing services is expected to continue growing as pharmaceutical companies prioritize core activities and seek external expertise.

Companies outsource analytical testing to gain access to state-of-the-art facilities, expertise, and specialized technologies without the need for heavy investments in infrastructure and personnel training. This trend is particularly pronounced among smaller pharmaceutical companies and startups with limited resources.

Key players in the Pharmaceutical Analytical Testing Outsourcing Market include contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and independent analytical laboratories. These entities offer a wide range of services, including method development and validation, stability testing, raw material testing, and quality control testing.

Factors driving the growth of this market include the increasing globalization of the pharmaceutical industry, the rising demand for specialized analytical techniques such as mass spectrometry and chromatography, and the growing emphasis on outsourcing non-core activities to focus on core competencies.

Despite the opportunities, the market faces challenges such as data security concerns, quality control issues, and the need for regulatory compliance. However, with the right strategies in place, the Pharmaceutical Analytical Testing Outsourcing Market is poised for continued growth and innovation in the coming years.

In 2022, the pharmaceutical analytical testing outsourcing market was estimated to be worth USD 4.2 billion. According to projections, the pharmaceutical analytical testing outsourcing market is expected to increase at a compound annual growth rate (CAGR) of 8.70% from USD 4.6 billion in 2023 to USD 7.5 billion by 2030.

Segmentation –

The global pharmaceutical analytical testing outsourcing market, by product type, has been segmented into finished products, active pharmaceutical ingredients, and raw materials. The finished products segment accounted for a value of USD 2,055.4 million in 2017. The market, by services, can be segmented into bioanalytical testing, method development & validation, stability testing, and others. On the basis of end user, the global pharmaceutical analytical testing outsourcing market is segmented into pharmaceutical & biopharmaceutical companies and biotechnology industry.

Regional Analysis –

The Pharmaceutical Analytical Testing Outsourcing Market exhibits diverse regional trends influenced by factors such as regulatory frameworks, technological advancements, and the presence of outsourcing service providers.

North America dominates the market, driven by stringent regulatory requirements, a robust pharmaceutical industry, and a high demand for outsourcing services to ensure compliance and product quality. The region also benefits from a mature outsourcing ecosystem and a strong network of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Similarly, Europe holds a significant market share, supported by a well-established pharmaceutical sector, favorable regulatory environment, and increasing emphasis on cost-effective solutions.

In Asia Pacific, the market is witnessing rapid growth fueled by the outsourcing trend among pharmaceutical companies, expanding healthcare infrastructure, and a skilled workforce at competitive costs. Latin America and the Middle East & Africa regions present opportunities for market expansion, driven by the growing pharmaceutical industry, improving regulatory landscape, and cost advantages. However, challenges such as quality control issues and intellectual property concerns may impact market growth in these regions. Overall, the Pharmaceutical Analytical Testing Outsourcing Market showcases a dynamic landscape across different regions, characterized by varying regulatory environments, outsourcing capabilities, and market demands.

Key Players –

Pharmaceutical analytical testing outsourcing companies include Boston Analytical (New Hampshire), West Pharmaceutical Services, Inc. (U.S.), Exova Group PLC (U.K.), Source BioScience (U.K.), Pace Analytical Services, Inc. (U.S.), Merck KGaA (Germany), WuXi AppTec (U.S.), Toxikon (U.S.), Eurofins Scientific (Belgium and Luxembourg), Intertek Group Plc (U.K.), Charles River Laboratories International, Inc (U.S.), SGS SA (U.K.), and Pharmaceutical Product Development, LLC (U.S.).

Related Reports –

Neurostimulation Devices

Crohn’s Disease

Healthcare Biometrics

Osteoporosis Drugs

For more information visit at MarketResearchFuture

[marketreports-blog]

The U.S. pharmaceutical analytical testing outsourcing market size was exhibited at USD 4.50 billion in 2023 and is projected to hit around USD 9.07 billion by 2032, growing at a CAGR of 8.1% during the forecast period 2023 to 2032.

[luckydige45]

The U.S. pharmaceutical analytical testing outsourcing market size was exhibited at USD 4.50 billion in 2023 and is projected to hit around USD 9.07 billion by 2032, growing at a CAGR of 8.1% during the forecast period 2023 to 2032.

[medicinemanufacturing]

Understanding the Role of CDMO Pharma Companies in the Drug Development Lifecycle

CDMO pharma companies are critical in accelerating drug development in today's pharmaceutical world. These Contract Development and Manufacturing Organizations (CDMOs) provide specialised services to pharmaceutical companies, ranging from early research and development to manufacturing and packaging, allowing businesses to bring life-saving pharmaceuticals to market more efficiently. CDMOs, with their experience in formulation, testing, and manufacturing, are critical industry partners who assist innovation while ensuring product safety and quality. 

Key Services Provided by CDMO Pharma Companies

A CDMO provides services throughout the drug development process. By collaborating with a CDMO, pharmaceutical businesses receive access to a broad spectrum of solutions, each geared to meet tight regulatory criteria and optimise product quality:

Formulation and Development: One of CDMOs' primary capabilities is drug formulation. CDMOs collaborate with pharmaceutical companies to create formulations that optimise a drug's stability, bioavailability, and effectiveness. A well-established CDMO can manage the special requirements of each formulation, whether oral, injectable, or topical.

Analytical Testing and Validation: Thorough testing is required to meet safety and regulatory requirements. CDMOs conduct extensive analytical testing to ensure a drug's purity, potency, and safety. This involves stability testing, technique validation, and FDA and regulatory criteria adherence. CDMOs use advanced laboratory facilities to verify that all drug formulations fulfil industry and market standards.

Clinical Trial Manufacturing: CDMOs supply clinical trial materials to support various study phases before full-scale production. From tiny batches for the Phase I study to larger volumes for Phase III, CDMOs help with the manufacturing process and provide experience in documentation, labelling, and shipping. This enables pharmaceutical businesses to maintain the quality and compliance required at each trial stage.

Commercial manufacture and Packaging: After a medicine is approved, CDMOs conduct large-scale manufacture to enable a smooth transition from clinical trials to commercial distribution. They also provide regulatory-compliant packaging services, ensuring each product is appropriately labelled and transported safely. CDMOs use innovative technologies to maximise production while maintaining strict quality control throughout the manufacturing and packaging.

Benefits of Partnering with a CDMO

Partnering with a CDMO provides pharmaceutical businesses with various benefits, including:

Faster Time-to-Market: CDMOs shorten the time it takes to bring a novel medicine to market by leveraging their established facilities, resources, and experience. Their skills enable speedier formulation, testing, and scaling, ensuring that life-saving drugs reach patients sooner.

Cost-effectiveness: CDMOs eliminate the need for pharmaceutical companies to invest in their production facilities, personnel, and equipment, which can be costly and time-consuming. Companies that outsource to a CDMO save money on capital and better manage their costs.

Access to Specialized Expertise: CDMOs employ highly skilled scientists, researchers, and technicians knowledgeable about regulatory standards and best practices. This knowledge is beneficial for navigating complex processes and maintaining compliance with strict requirements.

CDMO pharma companies are crucial partners throughout the drug development lifecycle, helping everything from preliminary research to commercial production. Their knowledge assists pharmaceutical businesses in navigating regulatory difficulties, reducing costs, and delivering high-quality pharmaceuticals to the market effectively. Companies who work with a reputable CDMO, such as Prakruti Life Sciences, get an ally dedicated to guiding them through the road from concept to market-ready product, ensuring quality at every level.

[ankitblogs0709]

Drug Discovery And Development Laboratory Services Market Forecast and Analysis Report (2023-2032)

The global demand for Drug Discovery And Development Laboratory Services was valued at USD 16845.8million in 2022 and is expected to reach USD 50819.0 Million in 2030, growing at a CAGR of 14.80% between 2023 and 2030.

Drug discovery and development laboratory services are essential to the pharmaceutical and biotech industries, supporting the journey from initial research to approved medications. These specialized laboratories conduct a wide range of activities, including target identification, assay development, high-throughput screening, and lead optimization, to identify potential drug candidates. Additionally, they provide essential preclinical testing, pharmacokinetics, toxicology studies, and bioanalytical services to evaluate the safety, efficacy, and pharmacological profiles of compounds before clinical trials. With increasing complexity in drug development, such as the rise of biologics and precision medicine, demand for specialized laboratory services has surged, driving advancements in automation, data analytics, and high-tech equipment. These services play a critical role in accelerating the drug discovery timeline, improving the success rates of therapeutic candidates, and helping companies navigate stringent regulatory requirements more effectively, ultimately contributing to faster and more efficient drug development pipelines.

The drug discovery and development laboratory services market presents several growth opportunities, driven by advancements in biotechnology, personalized medicine, and the increasing demand for efficient drug development processes. Here are some key growth areas:

Biologics and Biosimilars: The rise in biologics and biosimilars has created demand for specialized lab services, including bioassays, molecular biology, and immunogenicity testing, as companies seek reliable support for the development of complex biological drugs.

Precision and Personalized Medicine: The shift towards personalized medicine requires services like genetic profiling, biomarker discovery, and cell-based assays, creating opportunities for labs that offer these niche capabilities to support targeted therapies.

AI and Automation in Drug Discovery: Artificial intelligence and automation have become critical for enhancing drug discovery efficiency, allowing laboratories to conduct high-throughput screening and data analysis faster. Labs investing in AI-based platforms and robotic systems can offer faster, cost-effective services, making them attractive to pharmaceutical clients.

Increased Outsourcing by Pharmaceutical Companies: Pharmaceutical and biotech companies increasingly outsource drug development stages to specialized labs to reduce costs and focus on core competencies, creating significant demand for third-party laboratory services.

Growing Demand for Toxicology and Safety Testing: Regulatory bodies emphasize rigorous safety assessments, fueling demand for toxicology, pharmacokinetics, and bioanalytical services that ensure compliance and drug safety at every development stage.

Expansion in Emerging Markets: Emerging markets in Asia-Pacific, Latin America, and Eastern Europe offer growth opportunities due to rising healthcare investments, lower operational costs, and an expanding pharmaceutical sector, prompting global labs to establish facilities in these regions.

Collaborations with Academic and Research Institutions: Partnerships with academic institutions facilitate early-stage research and foster innovation, providing labs with fresh insights and potentially lucrative opportunities to collaborate on cutting-edge projects.

Development of Advanced Analytical Techniques: Techniques like CRISPR, next-generation sequencing, and advanced imaging provide expanded services for drug discovery, allowing labs to offer high-precision solutions for identifying drug candidates with improved accuracy.

Access Complete Report - https://www.credenceresearch.com/report/drug-discovery-development-laboratory-services-market

Key Players

General Electric (U.S.)

Eurofins Scientific (U.S.)

PPD Inc. (U.S.)

Syngene International Limited (India)

Wuxi AppTec (China)

Frontage Labs (U.S.)

Galapagos NV (Belgium)

Aurigene Discovery Technologies (India)

Genscript (U.S.)

Domainex (U.K.)

WIL Research Laboratories LLC (U.S.)

Shanghai Medicilon, Inc. (China)

Labcorp Drug Development (U.S.)

Jubilant Biosys Ltd. (India)

Evotec (Germany)

Shanghai ChemPartner (China)

Charles River Laboratories (U.S.)

Merck & Co. Inc. (U.S.)

Thermo Fisher Scientific Inc. (U.S.)

The drug discovery and development laboratory services market is undergoing rapid transformation, driven by several innovative trends that are reshaping the way drugs are researched, tested, and brought to market. Here are some key trends:

Artificial Intelligence and Machine Learning Integration: AI and ML are revolutionizing drug discovery by accelerating processes like target identification, lead optimization, and predictive modeling. These technologies allow laboratories to analyze vast datasets quickly, increasing the accuracy of drug target selection and reducing discovery timelines.

High-Throughput Screening Automation: Automation in high-throughput screening (HTS) enables labs to test thousands of compounds simultaneously. Robotic systems and automated workflows enhance efficiency, making HTS faster, more reliable, and cost-effective, which is essential for identifying potential drug candidates more quickly.

CRISPR and Gene Editing Technologies: CRISPR-based techniques have become instrumental in studying disease models and developing targeted therapies. These technologies allow labs to edit genes with precision, making them invaluable for identifying novel drug targets and accelerating preclinical research.

Advances in Biomarker Discovery: Biomarker discovery is increasingly central to developing targeted and personalized therapies. Advances in proteomics, genomics, and metabolomics enable labs to identify biomarkers more accurately, supporting the development of treatments tailored to specific patient populations.

Lab-on-a-Chip and Microfluidics: Miniaturization with lab-on-a-chip and microfluidic technologies enables precise control of experimental conditions on a small scale, reducing reagent use and allowing rapid, low-cost testing. These innovations are transforming assays and early-stage testing, increasing lab efficiency.

3D Cell Cultures and Organoids: Traditional 2D cell cultures are increasingly being replaced by 3D cultures and organoids, which provide more realistic models of human tissues. These models improve the accuracy of preclinical testing, reducing reliance on animal models and enhancing insights into drug efficacy and toxicity.

In Silico Drug Design and Virtual Screening: Computational approaches like in silico modeling and virtual screening allow labs to simulate interactions between compounds and targets, reducing the need for extensive physical testing. These tools can rapidly narrow down viable drug candidates, saving time and resources.

Expansion of Outsourcing and Partnerships: Many pharmaceutical companies are outsourcing parts of their drug discovery and development processes to specialized labs, fostering innovation and efficiency. Strategic partnerships with CROs (Contract Research Organizations) are becoming common, allowing companies to access expertise and advanced technologies without heavy investments.

Real-World Data Integration: The use of real-world data (RWD), including patient records and post-market surveillance, helps labs and pharmaceutical companies gain insights into drug safety and efficacy in diverse populations. RWD integration enables data-driven decisions that improve clinical trial design and outcomes.

Green Chemistry and Sustainable Practices: There is a growing emphasis on sustainability in drug development. Labs are adopting green chemistry principles, using eco-friendly solvents, and reducing waste to minimize their environmental impact, aligning with broader industry goals for sustainability.

Segmentation

By Bioanalytical Testing Services:

Pharmacokinetics (PK) and Pharmacodynamics (PD) Studies

By Drug Metabolism and Pharmacokinetics (DMPK) Services:

Metabolite Profiling

Plasma Protein Binding Studies

By Pharmaceutical Chemistry Services:

Synthetic Chemistry

Analytical Chemistry

By Cell Line Development and Engineering:

Cell Line Characterization

Cell Line Engineering

By Clinical Trial Services:

Clinical Laboratory Testing

Central Laboratory Services

By Genomic Services:

Genomic Sequencing

Genomic Data Analysis

By Proteomic Services:

Protein Expression and Characterization

Proteomic Profiling

By Pharmacovigilance and Safety Testing:

Adverse Event Monitoring

Safety Pharmacology Studies

By Quality Control and Assurance:

GMP (Good Manufacturing Practice) Testing

Quality Control Testing

By Technology Platforms:

Advanced Analytics

High-Throughput Screening (HTS)

Browse the full report –  https://www.credenceresearch.com/report/drug-discovery-development-laboratory-services-market

Contact Us:

Phone: +91 6232 49 3207

Email: sales@credenceresearch.com

Website: https://www.credenceresearch.com

[mordormr]

Exploring the Business Process Outsourcing (BPO) Market: Trends, Growth Drivers, and Future Outlook

The Business Process Outsourcing (BPO) industry has become a cornerstone of operational efficiency for organizations worldwide. By outsourcing non-core tasks to specialized providers, businesses can focus on strategic areas, improve efficiency, and reduce costs. According to recent market research, The Pharmaceutical Analytical Testing Market size is projected to be valued at USD 8.98 billion in 2024 and is anticipated to grow to USD 13.43 billion by 2029, with a CAGR of 8.41% over the forecast period from 2024 to 2029.

Key Trends in the BPO Market

Growth in Digital Transformation Initiatives Digital transformation has reshaped how companies view their business processes. Today, BPO providers offer more than just traditional services such as customer support and payroll processing—they are increasingly offering advanced technology solutions like AI-driven data analytics, automation, and cloud-based solutions. This enables businesses to gain real-time insights and make data-driven decisions, driving significant demand within the BPO sector.

Focus on Cost-Efficiency and Resource Optimization Many companies are turning to BPO to achieve cost savings. By outsourcing certain functions, organizations avoid the expense of hiring and training in-house staff for roles that may not be essential to their core business. Outsourcing also allows businesses to access skilled professionals without incurring high labor costs, making BPO services attractive to organizations of all sizes.

Shift to Knowledge Process Outsourcing (KPO) While traditional BPO services like customer support and IT outsourcing remain popular, there is a growing shift towards Knowledge Process Outsourcing (KPO). KPO involves outsourcing high-level tasks such as market research, data analytics, and legal services that require specialized expertise. As industries like healthcare, finance, and IT face complex regulatory environments, the demand for KPO services is on the rise.

Increasing Use of Automation and AI in BPO Services The integration of Robotic Process Automation (RPA) and Artificial Intelligence (AI) is transforming BPO services. These technologies enable BPO providers to handle repetitive tasks with greater accuracy and speed, reducing the need for human intervention and significantly lowering operational costs. Automation also allows for a quicker response time in customer service, providing a better experience for end-users.

Rising Demand for Multilingual Services As businesses expand globally, the need for multilingual customer support has grown. BPO providers are expanding their services to cater to this demand, offering customer service in multiple languages to help organizations maintain strong relationships with their global customer base.

Growth in Cloud-Based BPO Solutions The cloud has become essential for flexibility, scalability, and cost-effectiveness. Many BPO providers are now offering cloud-based services, which allow for easy access, data sharing, and remote work capabilities. This shift has enabled companies to keep pace with their outsourcing partners in real-time, enhancing collaboration and driving faster decision-making.

Key Sectors Utilizing BPO

BPO services cater to a variety of industries:

Finance and Accounting: Outsourcing functions like payroll processing, tax filing, and bookkeeping.

Healthcare: Medical billing, telemedicine, and patient support services.

Retail and E-commerce: Customer service, inventory management, and logistics.

Telecommunications: Customer support and network management.

IT Services: Helpdesk support, application management, and cybersecurity monitoring.

Future Outlook of the BPO Market

The BPO industry is expected to witness continued growth, especially as organizations increasingly prioritize digital transformation and seek to maximize their operational efficiency. Future developments in AI, machine learning, and process automation will likely shape the next generation of BPO services, focusing on reducing manual processes and providing intelligent insights for strategic decisions.

Conclusion

As companies increasingly embrace digital innovation and seek cost-effective solutions, the Business Process Outsourcing (BPO) market is primed for expansion. With a focus on process automation, knowledge process outsourcing, and cloud-based solutions, the BPO industry is set to remain a critical partner for businesses aiming to enhance their operational efficiencies and focus on their core strengths.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/business-processing-outsourcing-market  

[communicationblogs]

Failure Analysis Market — Forecast(2024–2030)

Overview

As the technology is evolving the tools for identifying and correction of failure has becoming easy and increase in usage of technology is driving the failure testing market With the complexity of electronic devices and materials continuously increasing, there’s a growing demand for more advanced analytical techniques in failure analysis. This includes techniques such as scanning electron microscopy (SEM), transmission electron microscopy (TEM), focused ion beam (FIB) microscopy, X-ray imaging, and spectroscopy. These techniques enable finer resolution, deeper analysis, and greater accuracy in identifying failure modes, thereby driving the adoption of sophisticated failure analysis solutions. Many companies are increasingly outsourcing their failure analysis needs to specialized service providers. Outsourcing offers several advantages, including access to expertise and equipment not available in-house, faster turnaround times, and cost savings. Additionally, as failure analysis becomes more specialized and requires highly skilled personnel and expensive equipment, outsourcing provides a more efficient and cost-effective solution for many organizations. As a result, the market for failure analysis services is witnessing significant growth, with specialized firms catering to a wide range of industries and applications.

These trends reflect the evolving needs and challenges in failure analysis and are driving innovation and growth in the market. However, it’s essential to consult more recent sources to confirm if these trends persist or if there have been new developments since my last update.

Request Sample

The report: “Failure Analysis Market — Forecast (2024–2030)”, by IndustryARC, covers an in-depth analysis of the following segments of the Barium Sulphate Industry. Market.

By Product: Transmission Electron Microscope, Focused Ion Beam Systems, Scanning Electron Microscopy, Dual Beam Systems, Others

By Test: Fractography, Metallography, Mechanical Testing, Chemical Analysis and Testing, NDT, Weld Testing, Microstructure Evaluation, Adhesive Identification, Coating

Contamination, Thermal Mapping, Electrical Overstress (EOS)/Electrostatic Discharge (EDS), Regulatory Compliance Testing, Others

By Techniques: Fault Tree Analysis (FTA), Common-Mode Failure Analysis, Failure Modes Effect Analysis (FMEA), Failure Modes, Effects and Criticality Analysis (FMECA), Functional Failure Analysis, Sneak Circuit Analysis, Software Failure Analysis, Others

By Technology: Broad ion milling, Focused ion milling, Relative ion etching, Secondary ion mass spectroscopy, Energy dispersive X-Ray Spectroscopy

By Application: Bio Science Cellular Biology, Neuroscience, Bio Medical, Others. Electronics: Semiconductors, Others. Renewable Energy: Solar, Wind. Agriculture: Machinery & Tools. Oil and Gas, Machinery & Tools. Commercial Aerospace.

Defense: Marine, Aerospace, Ground. Automotive: Automotive Materials Testing, Automotive Plastics and Polymers Physical Testing, Automotive Exterior Testing and Expertise, Automotive Interior Testing and Expertise. Construction. Chemical and Pharmaceutical. Healthcare Equipment. Food & Beverage. Mining. Polymer. Paper & Fiber material. Ceramic & Glass. Nanofabrication. Others.

By Geography: By Geography: North America (US, Canada and Mexico), Europe (UK, France, Germany, Italy, Spain, Russia, Netherlands, Belgium, and Rest of Europe), APAC (China, Japan, India, South Korea, Australia and New Zealand, Indonesia, Taiwan, Malaysia and Rest of APAC), South America (Brazil, Argentina, Colombia, Chile, Rest of South America), and RoW (Middle East and Africa).

Inquiry Before Buying

Key Takeaways

• Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level — for product types, end use applications and by different industry verticals.

• Understand the different dynamics influencing the market — key driving factors, challenges and hidden opportunities.

• Get in-depth insights on your competitor performance — market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.

• Analyze the sales and distribution channels across key geographies to improve top-line revenues.

• Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.

• Get a quick outlook on the market entropy — M&A’s, deals, partnerships, product launches of all key players for the past 4 years.

• Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.

Failure Analysis Market Segment Analysis — By Application

The automotive sector has seen notable technological advancements such as Advanced Driver Assistance Systems (ADAS), connected vehicles, Internet of Things (IoT) devices, and smart sensors. These innovations play a crucial role in preventing potential accidents caused by malfunctions in critical vehicle components. According to a June 2022 report from the World Health Organization (WHO), around 1.3 million lives are lost annually due to road traffic accidents, with 20 to 50 million individuals sustaining non-fatal injuries Potential causes of automotive device failures include aspects like product design, manufacturing processes, material source contamination, product packaging, mishandling, and incorrect calibration. These factors underscore concerns about the manufacturing quality of automotive parts and the necessity for proactive measures to mitigate incidents.The Asia-Pacific region has experienced significant growth in the automotive sector, fueled by increasing demand for both passenger and advanced vehicles. The region’s high population density contributes to elevated usage of passenger vehicles, thus driving market expansion. In 2022, China’s automotive industry alone produced approximately 23.8 million passenger cars, as reported by the International Organization of Motor Vehicle Manufacturers (OICA).

Failure Analysis Market Segment Analysis — Electronics & Semiconductor

The dominance of the electronics and semiconductor application segment in the failure analysis market is evident, holding the largest share. This is primarily attributed to the escalating demand for miniature transistor chips, Nano electronics, and optoelectronics across various industries. The electronics and semiconductor sector is emerging as a pivotal player, fueled by the rising adoption of robotics and automation in the manufacturing of electronic devices. This surge in automation has led to a requirement for high-density, integrated, and miniaturized devices to facilitate the production of smart devices, wearables, and intelligent industrial equipment. As a result, the need for robust failure analysis solutions within this sector has become increasingly pronounced, driving the dominance of the electronics and semiconductor segment in the market.

Failure Analysis Market Segment Analysis — Geography

During the projected period, the Asia Pacific region is expected to demonstrate the highest Market Share of 45 % The significant mass production of electronic goods such as smartphones, tablets, sensors, industrial equipment, wearables, and white goods in China and Taiwan is set to propel the expansion of the failure analysis market in this area. Japan holds a prominent position as the primary market for microscopy equipment in the Asia Pacific region. Major industry players like Nikon, JEOL Ltd., Olympus, and Hitachi High-Technologies are headquartered in Japan, enjoying strong patronage from major research institutions, pharmaceutical companies, and biotechnology firms. In China, the manufacturing sector is actively embracing industrial robots to automate and modernize various manufacturing processes. This transition has created a demand for monitoring device failures, presenting fresh growth prospects for the failure analysis market in the country.

Failure Analysis Market Share (%) By Region, 2023

Buy Now

Drivers — Failure Analysis Market

Fusion of Microscopy and Spectroscopy

The integration of microscopy with spectroscopy is poised to unlock significant opportunities across research communities, offering a wide array of applications. For instance, merging Raman spectroscopy with either atomic force microscopy or optical microscopy provides intricate insights into nanoscale properties and composition. The combined techniques synergize to facilitate precise sample alignment, efficient optical signal transfer from microscope to spectrometer, and accurate focusing of excitation light at the detection point.The potential of amalgamating microscopy technologies has led to innovations like the DXR2 Raman Imaging Microscope by Thermo Fisher Scientific. This instrument seamlessly integrates an optical microscope with a Raman spectrometer, allowing for the acquisition of both traditional optical and petrochemical images

Challenges — Failure Analysis Market

Elevated Ownership and Maintenance Expenses

There has been a noticeable shift in microscopy usage trends, with traditional models gradually being replaced by high-end alternatives such as electron microscopes, scanning probe microscopes, and digital microscopes. This transition is fueled by the advanced features, superior resolution, and magnification capabilities offered by these modern instruments. However, a significant barrier to their widespread adoption lies in their high cost, which can range from USD 25,000 to USD 2 million. This pricing hurdle limits their accessibility in settings like hospitals, pathological laboratories, and small-scale industries. Furthermore, the ongoing expenses associated with microscope maintenance add to the overall ownership costs. For instance, maintenance costs for a transmission electron microscope can fall within the range of USD 15,000 to USD 100,000 per year. These steep expenses often necessitate heavy reliance on government and private research funding, consequently restraining market growth to a certain extent.

Market Landscape

Failure Analysis Market Segment Analysis Market Landscape

Technology launches, acquisitions and R&D activities are key strategies adopted by players in the Window Films Market. Major players in the Failure Analysis Market are

Hitachi High-Tech, Intertek, JEOL, Motion X, TESCAN, ZEISS, A&D Company, Carl Zeiss SMT, FEI, Thermo Fisher Scientific and Others.

[health-views-updates]

Healthcare Contract Research Organization Market: Regional Dynamics and Emerging Opportunities

The global healthcare contract research organization market revenue is set for sustained growth, with a market size valued at USD 50.5 billion in 2023 and projected to expand to USD 88.07 billion by 2031. This reflects a compound annual growth rate (CAGR) of 7.2% during the forecast period from 2024 to 2031. The increasing demand for outsourcing clinical trials, rising R&D expenditures, and regulatory complexities are key drivers of this growth.

CROs provide essential outsourced services to pharmaceutical, biotechnology, and medical device companies, supporting the development and testing of new drugs and medical products. By offering expertise in clinical trials, data management, regulatory affairs, and more, CROs allow healthcare companies to focus on innovation while ensuring efficient, compliant, and cost-effective research processes.

Key Market Drivers

Rising R&D Expenditure in Pharmaceuticals and Biotechnology: The growing investment in research and development (R&D) by pharmaceutical and biotechnology companies is a major factor driving the CRO market. As the cost and complexity of clinical trials increase, companies are seeking external expertise to manage the regulatory, operational, and logistical challenges involved. CROs are well-positioned to provide specialized services that can accelerate drug discovery and development.

Increased Demand for Outsourcing Clinical Trials: The trend of outsourcing clinical trials to CROs is gaining momentum due to the benefits of cost savings, access to global expertise, and faster time to market. CROs help reduce the time and financial burden of conducting trials, particularly in multi-regional settings, where they can leverage their global infrastructure and local regulatory knowledge to manage trials more efficiently. This is particularly important in a highly competitive pharmaceutical landscape, where speed and accuracy are critical.

Complexity of Regulatory Requirements: Navigating the intricate and ever-changing landscape of regulatory requirements is a significant challenge for healthcare companies. CROs offer valuable expertise in managing regulatory submissions, compliance with global standards, and post-market surveillance. Their ability to keep up with evolving regulations and ensure adherence to protocols is critical for companies seeking to bring new therapies to market.

Growing Focus on Precision Medicine and Personalized Therapies: The increasing focus on precision medicine and the development of personalized therapies is creating new opportunities for CROs. These innovative approaches require highly specialized clinical trials, data analytics, and patient monitoring, all of which CROs are well-equipped to handle. The need for tailored solutions is driving pharmaceutical and biotech companies to partner with CROs that have expertise in specific therapeutic areas and technologies.

Expansion of Biologics and Biosimilars Development: The development of biologics and biosimilars is another significant growth driver for the CRO market. These complex therapies require extensive testing and regulatory approval, making CROs an essential partner in ensuring compliance with stringent quality standards. As the demand for biologics and biosimilars increases, so does the need for reliable and efficient CRO services.

Challenges and Opportunities

Despite the market's strong growth potential, challenges such as high competition among CRO providers and evolving pricing pressures could pose hurdles. Small and mid-sized CROs, in particular, may face difficulties in competing with large, established players that can offer end-to-end services and operate on a global scale.

However, the increasing adoption of advanced technologies, such as artificial intelligence (AI), machine learning, and real-world evidence (RWE) in clinical trials, presents new opportunities for CROs. These innovations can improve trial efficiency, enhance data accuracy, and shorten development timelines, making CRO services even more valuable to healthcare companies.

Additionally, the rise of decentralized clinical trials (DCTs) and virtual trials, which leverage telemedicine and digital tools to conduct trials remotely, is expected to transform the CRO landscape. As DCTs gain popularity, CROs will play a pivotal role in facilitating the remote collection of data, patient monitoring, and regulatory compliance.

Regional Insights

North America remains the largest market for healthcare CROs, driven by the presence of major pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and favorable regulatory frameworks. Europe follows closely, with strong government support for clinical research and innovation in healthcare.

The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, due to the increasing prevalence of diseases, rising healthcare investments, and the growing number of clinical trials conducted in countries such as China, India, and Japan. The region offers cost advantages and access to a diverse patient population, making it an attractive destination for clinical trials.

Future Outlook

The healthcare CRO market is poised for significant expansion as the demand for outsourcing services continues to rise. With a projected CAGR of 7.2% from 2024 to 2031, the market is expected to grow from USD 50.5 billion in 2023 to USD 88.07 billion by 2031. Innovations in clinical trial methodologies, the growing focus on precision medicine, and the continued expansion of biologics and biosimilars will further fuel the market's growth.

In conclusion, the healthcare CRO market is entering a new phase of development, driven by increasing R&D investments, regulatory complexities, and the growing need for efficient clinical trial management. As the healthcare industry continues to evolve, CROs will play an increasingly critical role in supporting the development of innovative therapies and ensuring the successful commercialization of new products.

Other Trending Reports

Rotator Cuff Injury Treatment Market Outlook

Dermal Filler Market Outlook

Recombinant Vaccines Market Outlook

Computer Vision in Healthcare Market Outlook

[blog-site-for-market-research]

Navigating the Dynamics of Pharmaceutical Analytical Testing Outsourcing Market Industry

Market Overview –

The Pharmaceutical Analytical Testing Outsourcing Market is experiencing robust growth as pharmaceutical companies increasingly outsource their analytical testing needs to specialized service providers. Analytical testing is crucial in the pharmaceutical industry for ensuring the safety, quality, and efficacy of drug products.

Outsourcing Analytical Testing in the pharmaceutical industry is witnessing significant traction as companies seek cost-effective and specialized solutions. Outsourcing firms offer expertise in analytical testing, ensuring regulatory compliance and quality assurance. This trend is driven by the complexity of testing requirements and the need for efficient resource allocation. The market for outsourcing analytical testing services is expected to continue growing as pharmaceutical companies prioritize core activities and seek external expertise.

The market is driven by several factors, including the growing complexity of drug formulations, stringent regulatory requirements, and the need for specialized expertise and equipment. Outsourcing analytical testing allows pharmaceutical companies to access state-of-the-art facilities and specialized skills without making significant investments in infrastructure and personnel.

Moreover, outsourcing offers flexibility, scalability, and cost-effectiveness, enabling companies to streamline their operations and focus on core activities such as drug discovery and development. As a result, outsourcing analytical testing has become a strategic imperative for many pharmaceutical companies, driving the growth of the market.

Key players in the market range from contract research organizations (CROs) to specialized analytical testing laboratories, offering a wide range of services, including method development, validation, stability testing, and quality control.

The pharmaceutical analytical testing outsourcing market is also witnessing increasing demand from emerging markets, where pharmaceutical companies seek to leverage cost advantages and access local expertise. Additionally, the COVID-19 pandemic has further accelerated the adoption of outsourcing as companies strive to meet growing demand for testing services while managing disruptions to their operations.

Overall, the pharmaceutical analytical testing outsourcing market is expected to continue its expansion, driven by the growing demand for high-quality analytical services, regulatory compliance, and operational efficiency within the pharmaceutical industry.

In 2022, the pharmaceutical analytical testing outsourcing market was estimated to be worth USD 4.2 billion. According to projections, the pharmaceutical analytical testing outsourcing market is expected to increase at a compound annual growth rate (CAGR) of 8.70% from USD 4.6 billion in 2023 to USD 7.5 billion by 2030.

Segmentation –

The global pharmaceutical analytical testing outsourcing market, by product type, has been segmented into finished products, active pharmaceutical ingredients, and raw materials. The finished products segment accounted for a value of USD 2,055.4 million in 2017. The market, by services, can be segmented into bioanalytical testing, method development & validation, stability testing, and others. On the basis of end user, the global pharmaceutical analytical testing outsourcing market is segmented into pharmaceutical & biopharmaceutical companies and biotechnology industry.

Regional Analysis –

The Pharmaceutical Analytical Testing Outsourcing Market exhibits diverse regional trends influenced by factors such as regulatory frameworks, technological advancements, and the presence of outsourcing service providers.

North America dominates the market, driven by stringent regulatory requirements, a robust pharmaceutical industry, and a high demand for outsourcing services to ensure compliance and product quality. The region also benefits from a mature outsourcing ecosystem and a strong network of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Similarly, Europe holds a significant market share, supported by a well-established pharmaceutical sector, favorable regulatory environment, and increasing emphasis on cost-effective solutions.

In Asia Pacific, the market is witnessing rapid growth fueled by the outsourcing trend among pharmaceutical companies, expanding healthcare infrastructure, and a skilled workforce at competitive costs. Latin America and the Middle East & Africa regions present opportunities for market expansion, driven by the growing pharmaceutical industry, improving regulatory landscape, and cost advantages. However, challenges such as quality control issues and intellectual property concerns may impact market growth in these regions. Overall, the Pharmaceutical Analytical Testing Outsourcing Market showcases a dynamic landscape across different regions, characterized by varying regulatory environments, outsourcing capabilities, and market demands.

Key Players –

Pharmaceutical analytical testing outsourcing companies include Boston Analytical (New Hampshire), West Pharmaceutical Services, Inc. (U.S.), Exova Group PLC (U.K.), Source BioScience (U.K.), Pace Analytical Services, Inc. (U.S.), Merck KGaA (Germany), WuXi AppTec (U.S.), Toxikon (U.S.), Eurofins Scientific (Belgium and Luxembourg), Intertek Group Plc (U.K.), Charles River Laboratories International, Inc (U.S.), SGS SA (U.K.), and Pharmaceutical Product Development, LLC (U.S.).

Related Reports –

Oral Cancer Diagnostics

Automatic Pill Dispenser

Lancet

Medical Oxygen Concentrators

For more information visit at MarketResearchFuture

[lanettcdmo]

The Role of Contract Development and Manufacturing Organizations (CDMOs) in the Pharmaceutical

 

 Introduction

In the ever-evolving pharmaceutical and biotech industries, Contract Development and Manufacturing Organizations (CDMOs) have become essential players. They support drug developers by offering a comprehensive range of services, from initial drug development to large-scale production. In this blog, we’ll explore the role, benefits, and trends of CDMOs.

1. What is a CDMO?

A Contract Development and Manufacturing Organization (CDMO) is a company that offers services ranging from drug development to manufacturing, enabling pharmaceutical firms to outsource parts of their process. CDMOs are often seen as critical partners for both small biotech startups and large pharmaceutical companies.

Services Offered by CDMOs:

Drug Development: Preclinical and clinical development, formulation.

Analytical Services: Quality control, stability testing, regulatory support.

Manufacturing: Production at various scales (pilot, clinical, commercial).

Packaging and Distribution.

2. Why CDMOs are Critical to the Pharma Industry

Pharmaceutical companies increasingly turn to CDMOs for reasons including:

Cost Efficiency: Outsourcing reduces infrastructure and labor costs.

Speed to Market: Accelerates development timelines by leveraging expertise.

Focus on Core Strengths: Allows pharma companies to focus on innovation and commercialization rather than in-house production.

3. Key Advantages of Working with CDMOs

Expertise and Experience: CDMOs possess technical and regulatory expertise.

Flexibility and Scalability: They offer scalable solutions tailored to the project's needs, whether for small-scale clinical batches or full-scale commercial production.

Regulatory Compliance: CDMOs are well-versed in global regulatory standards, ensuring compliance with FDA, EMA, and other bodies.

4. CDMOs and Biotech Startups

For small biotechnology firms with limited resources, CDMOs provide access to cutting-edge technologies and capabilities. Startups can avoid significant capital investment by outsourcing drug development and manufacturing, focusing on research and innovation.

5. Trends in the CDMO Industry

The CDMO sector continues to evolve with the following trends shaping its future:

Biologics and Advanced Therapies: The rise of biologics, cell, and gene therapies has driven demand for specialized CDMOs.

Digitalization: The integration of AI, IoT, and data analytics is improving efficiency and quality control.

Sustainability and Green Manufacturing: As environmental concerns grow, CDMOs are adopting eco-friendly manufacturing practices.

Partnerships and Consolidations: Mergers and acquisitions have increased as CDMOs expand capabilities and global reach.

6. How to Choose the Right CDMO Partner

Selecting the right CDMO is critical for successful drug development and manufacturing. Key factors include:

Technical Expertise: Ensure the CDMO has the required technical and regulatory knowledge for your specific product type.

Track Record: Check their experience in handling similar projects.

Capacity and Flexibility: Verify whether the CDMO can scale up production if needed.

Quality Standards and Compliance: Ensure they follow GMP guidelines and other regulatory requirements.

Conclusion

As pharmaceutical companies look for ways to streamline their operations and bring new therapies to market faster, CDMOs will continue to play a pivotal role. By providing essential services at various stages of drug development and manufacturing, they are indispensable partners in the journey from laboratory to patient.

[industrynewsupdates]

Clinical Trials Procurement Intelligence 2024-2030: What You Need to Know

This clinical trials market is anticipated to grow at a CAGR of 6.49% from 2024 to 2030. North America is the leading region in this category, accounting for over 50.3% of the market share in 2023. This is expected to continue in the forecast period as well, due to several factors, including increased R&D investments and the adoption of new technologies. For example, the use of virtual services in clinical trials is becoming increasingly popular, and this is expected to drive growth in the North American market.

This category is driven by many key factors, including the surge in demand for outsourcing clinical trials, the increasing prevalence of chronic diseases, and the increased investments in R&D by pharmaceutical and biotechnological companies. The outsourcing of this category is becoming increasingly popular, as it allows pharmaceutical companies to focus on their core competencies and to save time and money. The increasing prevalence of chronic diseases is also driving the demand for clinical trials, as there is a need for the development of new and efficient therapeutics to treat these diseases. Also, the increased investments in R&D by pharmaceutical and biotechnological companies are driving the growth of the market, as these companies are constantly developing new drugs and therapies that need to be tested in clinical trials.

This category is a moderately fragmented market due to the presence of numerous players. Strategic alliances between pharmaceutical firms and CROs are anticipated to have a substantial impact on the category’s expansion. Additionally, the swift uptake of new technology for better healthcare contributes to the market's expansion. For instance,

• In November 2022, Calit Health Services (Israel) and IQVIA (US) announced a collaboration to work on clinical trial delivery. The collaboration will combine Calit's extensive clinical trial experience and IQVIA's global reach and expertise in data analytics.

• In April 2022, Charles River Laboratories, a pharmaceutical company that provides preclinical and clinical laboratory services, acquired Explora BioLabs, a provider of contract vivarium research services. This acquisition will allow Charles River to expand its offerings in the cell and gene therapy space.

• In February 2022, Citeline and Norstella merged to form a new company worth $5 billion. Citeline provides clinical trial management software, while Norstella provides clinical trial supplies and services. The merger of these two companies will allow them to offer a more comprehensive suite of services to pharmaceutical companies, which could help speed up the drug development process and improve patient access to new therapies.

Order your copy of the Clinical Trials Procurement Intelligence Report, 2024 - 2030, published by Grand View Research, to get more details regarding day one, quick wins, portfolio analysis, key negotiation strategies of key suppliers, and low-cost/best-cost sourcing analysis

Technological advancements in this category have revolutionized the drug development process by reducing costs and increasing efficiency. With rising trial expenses, failure rates, and a focus on patient-centric trials, the demand for the technology in clinical trials has surged. The landscape of clinical trials is evolving towards decentralization with the utilization of wearables, mHealth, and real-world evidence (RWE). These disruptive technologies enable small, controlled trials and streamline processes from patient enrollment to medication administration and follow-ups through mobile devices. Pharmaceutical companies are investing heavily in AI and big data analytics to leverage their transformative impact on the R&D process, enhance competitiveness, and facilitate company transformation and agility. Additionally, the integration of wearable devices and remote sample collection offers a safer and more convenient experience for participants, potentially increasing patient enrollment and engagement in future studies.

Defining the price and cost of this category is complex as it is dependent on various factors like phase, drug type, and location. Costs range from millions to billions, divided into patient care and research costs. Patient care costs include recruitment, enrollment, medication, safety monitoring, while research costs cover design, implementation, data analysis, and results publication. When budgeting for a clinical trial, consider various cost segments like regulatory, safety, data, quality management, overhead, and site costs. The price of this category is determined by the trial sponsor, typically a pharmaceutical company. Various factors can influence the trial's price, including its scale, complexity, and associated risks. Sponsors take these factors into account when setting the price, as they impact the resources required to conduct a successful trial.

When it comes to sourcing of this category, it is crucial to follow the best practices to ensure the high quality and integrity of the study. These practices include identifying reputable trial sites, evaluating investigator qualifications, prioritizing patient safety, assessing site capabilities, reviewing ethical considerations, evaluating data management systems, monitoring compliance with regulations, conducting site visits and audits. Additionally, it is essential to prioritize suppliers who offer comprehensive documentation, including certificates of analysis and trials conducted. By following these best practices, sponsors can enhance the quality, reliability, and ethical standards of their clinical trials. Finally, considering suppliers who engage in continuous research and development efforts can be beneficial for this category.

Clinical Trials Procurement Intelligence Report scope

• Clinical Trials Category Growth Rate: CAGR of 6.49% from 2024 to 2030

• Pricing Growth Outlook: 2% - 3% (Annually)

• Pricing Models: Unit-based pricing

• Supplier Selection Scope: Cost and pricing, Past engagements, Productivity, Geographical presence

• Supplier selection criteria: Reviewing ethical considerations, prioritizing patient safety, regulatory standards and mandates, category innovations, and others

• Report Coverage: Revenue forecast, supplier ranking, supplier matrix, emerging technology, pricing models, cost structure, competitive landscape, growth factors, trends, engagement, and operating model

Browse through Grand View Research’s collection of procurement intelligence studies:

• Clinical IT Services Procurement Intelligence Report, 2023 - 2030 (Revenue Forecast, Supplier Ranking & Matrix, Emerging Technologies, Pricing Models, Cost Structure, Engagement & Operating Model, Competitive Landscape)

• Clinical Staffing Services Procurement Intelligence Report, 2023 - 2030 (Revenue Forecast, Supplier Ranking & Matrix, Emerging Technologies, Pricing Models, Cost Structure, Engagement & Operating Model, Competitive Landscape)

Key companies profiled

• IQVIA

• PAREXEL International Corporation

• Pharmaceutical Product Development

• Charles River Laboratory

• ICON Plc

• Syneos Health

• Chiltern International Ltd

• Eli Lilly and Company

• Pfizer

• Caidya

Brief about Pipeline by Grand View Research:

A smart and effective supply chain is essential for growth in any organization. Pipeline division at Grand View Research provides detailed insights on every aspect of supply chain, which helps in efficient procurement decisions.

Our services include (not limited to):

• Market Intelligence involving – market size and forecast, growth factors, and driving trends

• Price and Cost Intelligence – pricing models adopted for the category, total cost of ownerships

• Supplier Intelligence – rich insight on supplier landscape, and identifies suppliers who are dominating, emerging, lounging, and specializing

• Sourcing / Procurement Intelligence – best practices followed in the industry, identifying standard KPIs and SLAs, peer analysis, negotiation strategies to be utilized with the suppliers, and best suited countries for sourcing to minimize supply chain disruptions